Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Journal of Clinical Microbiology and Infectious Diseases
Ni Luh Putu Harta Wedari
Clinical Microbiology Specialist Program, Faculty of Medicine, Universitas Udayana, Prof. Dr. I.G.N.G. Ngoerah Hospital, Bali, Indonesia
Immunology & microbiology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Modifications in Adenoviral vectors to enhance its tropism: a literature review Erly Sintya; Ni Luh Putu Harta Wedari; Ni Nyoman Sri Budayanti; Ni Luh Made Mirah Rahayu
Journal of Clinical Microbiology and Infectious Diseases Vol. 2 No. 2 (2022): Available Online: December 2022
Publisher : Indonesian Society for Clinical Microbiology (Perhimpunan Dokter Spesialis Mikrobiologi Klinik Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/jcmid.v2i2.32

Abstract

Viruses’ high rate of cellular entry raises the possibility that they could be utilized as vectors to introduce new functional copies of a gene into a cell. This review aims to explore modifications in Adenoviral vectors to enhance its tropism. It is feasible to exploit the infection pathway to achieve a therapeutic objective without the following expression of viral genes, which, if expressed, would cause disease and damage. It has been demonstrated that this is achievable. This is performed by swapping a therapeutic gene with an existing harmful gene in the genome of the virus. Due to its unique features, adenovirus, commonly known as Ad, is an intriguing possibility for use as a viral vector in gene therapy. Despite this, therapeutic applications of ad vectors are limited due to their immunogenicity and broad native tropism. Several distinct forms of nonimmunogenic polymers are utilized in the chemical or physical modification of ad vectors to circumvent these obstacles. In this review, many modifications, including capsid pseudotyping, serotype switching, and multiple conjugation-based techniques, are discussed in order to boost the specificity of target adenoviruses.
Implementation of antinuclear antibodies in autoimmune diagnostic tests: a literature review from immunological aspects Ni Luh Putu Harta Wedari; Ni Nyoman Sri Budayanti; I Dewa Made Sukrama; I Putu Bayu Mayura
Journal of Clinical Microbiology and Infectious Diseases Vol. 2 No. 2 (2022): Available Online: December 2022
Publisher : Indonesian Society for Clinical Microbiology (Perhimpunan Dokter Spesialis Mikrobiologi Klinik Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/jcmid.v2i2.33

Abstract

Antinuclear antibodies (ANA) test is mainly used in confirming autoimmune disorders such as systemic lupus erythematosus (SLE) and connective tissue diseases e.g., Sjogren’s Syndrome and rheumatoid arthritis. ANA test is often being used as a screening tool for further serological examination. This review aims to explore immunological aspects of anti-nuclear antibodies implementation in autoimmune diagnostic tests. Fluorescent antinuclear antibody (FANA) tests are often being applied since they have high sensitivity and are pretty simple to perform, however, this test has low specificity in diagnosis. In doing this method, patient samples are first diluted then incubated with Hep-2 cells or mouse kidney in glass slides in order to proceed specific binding of antinuclear antibodies. Roughly, around 2% of healthy people and 75% of elderly are positive for FANA test. In contrast, around 5% of people suffering from SLE are negative. Even though it is only seen in 50% up to 70% of SLE patients, ds-DNA antibodies are still the main confirmatory diagnostic gold standard for SLE, particularly in the low amount of C3 complement. Beside ANA, the other diagnostic tests considerably applied are complete blood count test, level of muscle enzyme serum, CXCL4 serum level. Paediatric patients with PM-scleroderma overlapping have been revealed to possess strong positive ANA; anti-Ro/SSA antibody is considered to be the most frequent myositis associated antibody (MAA) in myositis patients.
Co-Authors Erly Sintya I Dewa Made Sukrama I Putu Bayu Mayura Ni Luh Made Mirah Rahayu Ni Nyoman Sri Budayanti Ni Nyoman Sri Budayanti